Articles On Race Oncology (ASX:RAC)

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the shortened week with a small gain. At the time of writing, the benchmark index is up 0.2% to 6,805.7 points. Four ASX shares that have failed to follow the mark...

Source:WHYFRAME, Shutterstock Summary Huge market volatility has been observed in 2021 so far amid the tug of war between surging COVID-19 cases and progress in economic recovery. Volatility is expected to continue over the coming day...

The Race Oncology Ltd (ASX: RAC) share price is struggling in early-morning trade despite the company announcing the initiation of an extramedullary AML preclinical study. At the time of writing, the specialty pharmaceutical company’s shar...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

The ASX finished the day slightly in the green, dragged down by tech stocks which lost nearly 1.5 per cent and new float Airtasker (ASX:ART) fell by over 20 per cent. Airtasker debuted at 65 cents and rose over Tuesday and Wednesday to over...

Source: Tyler Olson, Shutterstock Summary ASX-listed oncology player Race Oncology to explore the use of Bisantrene for the treatment of ccRCC. 4DMedical to secure contracts with DoD and VA facilities for its XV LVAS with a pre-agreed...

Race Oncology Ltd (ASX: RAC) shares are slipping in late morning trade despite the company providing a positive update. At the time of writing, the Race share price has slumped 1.27% lower to $3.90. Below we take a look at the ASX healthca...

On this day last year, global stocks capped off a historic one-month collapse with another epic fall. While no one knew at the time, that marked the COVID-19 nadir. Over the course of the following week, governments around the world said ju...

Source: Blue Planet Studio, Shutterstock Summary Oncology player Race Oncology has collaborated with the University of Newcastle for its preclinical research program to study Bisantrene in melanoma. Leading Australian diagnostics play...

The Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new preclinical study by the specialty pharmaceutical company. At the time of writing, shares are down 0.5% to $3.98. Race Oncology share price un...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: fizkes ,Shutterstock Summary Race Oncology announced the positive final results of its preclinical research program for Bisantrene. The results demonstrated that Bisantrene was an effective cancer treatment for genetically dis...

The Race Oncology Ltd (ASX: RAC) share price is 9.4% higher at the time of writing following preclinical breast cancer results.  Race Oncology share price on the move after compelling results  Race Oncology is developing a cancer-fighting...

At the end of January, the GameStop Corp. (NYSE: GME) share price hit an all-time high of US$483. Only 2 months previously, shares in the company were trading at US$14.75. Many attributed the video game retailer’s dramatic rise to subreddi...

In February, ASX fintech stocks were winners, losers and winners again. The benchmark ASX 200 index made a 1 per cent gain for month – despite a late month drop — driven largely by favourite fintech Zip (ASX:Z1P) +43%, as well as Virgin Mon...

Source: ImageFlow,Shutterstock Summary Momentum investing is a relatively newer approach that primarily capitalises on the share price momentum. TPC consolidated has started March 2021 with a bang, delivering 23.81 per cent on Monday....

Source: schankz, Shutterstock Summary The Australian share market’s outlook appears exciting as the economy recovers from the coronavirus-induced disruptions.  The investors could use the opportunity to beef up their portfolios with s...

Hot on the heels of yesterday’s gains, Race Oncology Ltd (ASX: RAC) shares were marching higher again today. By the market’s close, the Race Oncology share price had jumped 2.27% to $3.15. That puts the total gains for the company’s shares...

Race Oncology (ASX:RAC) has released further interim results from its continuing collaborative preclinical research program with The University of Newcastle.

The Race Oncology Ltd (ASX: RAC) share price rocketed 20.98% today, closing the day at $2.48 per share. Race Oncology Ltd (RAC) is an Australian pharmaceutical company with developments in the cancer field. The company produces a chemother...

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

Summary The intensity of adoption of tech-enabled health solutions has shot up amidst government restrictions and infection risks amidst COVID-19. Burgeoning demand for healthcare products kept healthcare stocks under the spotlight in...

The rebound in the S&P/ASX 200 Index (Index:^AXJO) might be grabbing headlines with its dramatic rebound, but it’s the ASX small caps that’re outperforming. What’s more, the market minnows might keep their lead as we head into 2021 wit...

ShareCafeHidden Gems Webinar Recap – OSP, PYG, AGC, RAC Catch up on the full webinar with presentations from Osprey Medical Inc (ASX: OSP), Paygroup Limited (ASX: PYG), Australian Gold and Copper Limited (ASX:AGC) and Race Oncology Limited...

ShareCafeRace Oncology Limited (ASX:RAC) – Hidden Gems Webinar Presentation Presenter – Dr Daniel Tillett – Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene. Bisantrene is a potent...

At time of writing the RAC share price is trading at $2.12 up 7.07%. Race Oncology Ltd (ASX:RAC) announced the initiation of a breast cancer clinical trial program... The post Race Oncology Share Price Reaches New High (ASX:RAC) appeared fi...

Race Oncology (ASX: RAC) has shared the results of the preclinical research program it is undertaking as part of a collaboration with The University of Newcastle.

ASX-listed oncology drug developer Race Oncology Limited (ASX:RAC) today updated the market with its impressive results from the preclinical study of Bisantrene in breast cancer. The study results demonstrate that Bisantrene can kill some b...

Race Oncology (ASX: RAC) has unveiled what it describes as “impressive” results in preclinical breast cancer research using its bisantrene drug. The company undertook a collaborative preclinical research program with The University of Newca...

Summary Race Oncology announced that its Phase 2 clinical trial data of bisantrene had been published in the European Journal of Haematology. The results from the clinical study demonstrated an impressive clinical response rate of 40% i...

With biotechnology in focus in 2020, Race Oncology is attracting investor interest. -2020 booming times for (some) biotechnology stocks-Race Oncology aiming to revive 1980’s Acute Myeloid Leukemia (AML) treatment-Bisantrene clinical trials...

Race Oncology (ASX:RAC) has announced it has secured a new patent on its cancer drug, bisantrene, from the US Patent and Trademarks Office.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Cancer has long been one of the great evils of healthcare. It is easily one of the most insidious and prolific group of diseases society has dealt with. A burden that we are constantly struggling to find better ways to deal with. We are mak...

A quick wrap of the key winners and losers on Tuesday, June 16. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. The benchmark ASX200 Index bounced b...

Specialty pharmaceutical company Race Oncology (ASX: RAC) has reported positive data from an investigator-initiated Phase II clinical trial of historical cancer drug Bisantrene on patients with relapsed or refractory acute myeloid leukaemia...

The Race Oncology Ltd (ASX: RAC) share price has shot out of the gates this morning on the back of positive clinical trial results. Race Oncology shares opened 74.6% higher today and raced to an intra-day high of 60 cents in early trade –...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more often than not...

The perception of cancer as one incurable disease is wrong, according to a director of one of the ASX’s most prominent cancer fighters. Phillip Lynch, who joined the board of Race Oncology (ASX:RAC) last week, says cancer is a war fought on...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Despite March being a tough month to raise capital for ASX small caps, the money was still flowing for the gold explorers. In March, ASX small caps raised $72.2m, a steep decline from the $125m raised in February. Even in January, tradition...

Pharmaceutical company Race Oncology (ASX: RAC) has come out of a trading halt this morning to announce $1.8 million new equity funding via a strategic placement of 6 million shares. The $0.30 per share issue price represents a 9% discount...

Businesses will take any opportunity to cash in on a crisis and the latest move to profit from the coronavirus outbreak has been made by dietary supplement maker Eagle Health Holdings (ASX:EHH). After announcing it was partnering up with Zo...

With the health and life science sector being the ASX’s top performer last year, Western Australia is keen to join the party. The state government has formed an Industry Reference Group to come up with a five-year growth plan for the indust...

Race Oncology (RAC) has updated the market on its activities for the December 2019 quarter The company launched a 5-path clinical strategy for its cancer drug called Bisantrene Bisantrene is targeting cancers beyond Acute Myeloid Leukaemia...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

Every week Stockhead publishes a weekly column of directors trades of $100,000 or more among ASX small caps. As 2019 draws to a close, we thought we could re-cap the most noteworthy trades.   Biggest trade Wagners (ASX:WGN) co-founders Deni...